Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

NHLBI TOPMed: My Life, Our Future – Genotyping for Progress in Hemophilia

ABSTRACT: NHLBI TOPMed: My Life, Our Future – Genotyping for Progress in Hemophilia

PROVIDER: PRJNA423127 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

NHLBI TOPMed: My Life, Our Future – Genotyping for Progress in Hemophilia

Project description:NHLBI TOPMed: My Life, Our Future – Genotyping for Progress in Hemophilia

| PRJNA423126 | ENA

MY-CLIP verification study

Project description:Comparison between BrdU-CLIP and MY-CLIP for HNRNPU, and MY-CLIP performance for HNRNPC

2020-03-31 | GSE138649 | GEO

MY-CLIP verification study

Project description:MY-CLIP verification study

| PRJNA576684 | ENA

Hemophilia mice treated with antisense oligonucleotides targeting either Upf1 or Upf3b

Project description:Hemophilia mice were treated for one month with ASOs targeting either Upf1 or Upf3b. The liver RNAs were extracted and analyzed

2017-11-03 | GSE106436 | GEO

HNRNPU MY-CLIP study using cytoplasmic or whole lysates

Project description:Comparison of MY-CLIP between using cytoplasmic fraction and whole cell lysate for PMA/Ca2+ ionophore stimuated HeLa cells

2020-03-31 | GSE138661 | GEO

My short study

Project description:My short descrtiptive title for the study

| PRJEB14416 | ENA

A CpG mutational hotspot in a ONECUT (HNF6) binding site accounts for the prevalent variant of Hemophilia B Leyden

Project description:Hemophilia B, or the 'Royal Disease', arises from mutations in the Coagulation Factor IX (F9) gene. Mutations within the F9 promoter are associated with a remarkable form of the disease, termed Hemophilia B Leyden, in which symptoms ameliorate after puberty. Mutations at the -5/-6 site account for the majority of Leyden cases, and have been postulated to disrupt the binding of a transcriptional activator, the identity of which has remained elusive for more than twenty years. Here we show that the ONECUT transcription factors (ONECUT1/HNF6 and ONECUT2/HNF6B) bind to the -5/-6 site. The various Hemophilia B Leyden mutations that have been reported in this site inhibit ONECUT binding to varying degrees that correlate well with their associated clinical severities. In addition, expression of F9 is crucially dependent on ONECUT factors in vivo and as such, mice that are deficient in either ONECUT1, ONECUT2 or both, exhibit depleted levels of F9. Taken together, our findings establish the ONECUT transcription factors as the missing regulators of Hemophilia B Leyden that operate through the -5/-6 site.

2013-03-06 | E-MTAB-890 | biostudies-arrayexpress

PROGRESS/ELEMENT DNA Methylation Study

Project description:PROGRESS/ELEMENT DNA Methylation Study

| PRJNA792632 | ENA

PROGRESS/ELEMENT DNA Methylation Study

Project description:PROGRESS/ELEMENT DNA Methylation Study

| PRJNA792633 | ENA

Inhibition of xCT Suppresses Melanoma progress

Project description:Inhibition of xCT Suppresses Melanoma progress

| PRJNA701281 | ENA